SOX2 overexpression have been broadly observed in various cancers and treated as a critical diver in cancer occurrence and progression.29–31 In osteosarcoma, it has been reported that aberrant expression of SOX2 promotes tumor initiation and proliferation.24,32 In this study we found SOX2 is highly expressed in osteosarcoma tissues and correlates poor survival of OS patients (Fig. 1) and plays an essential role in tumor growth, metastases and chemoresistance (Figs. 2, 5 and 6), indicating that SOX2 is a central target for OS treatment. This evidence concerns the gene SOX2 and osteosarcoma.